【摘要】 目的通过观察阿帕替尼联合的新辅助治疗的疗效,为SiewertⅠ型贲门癌的新辅助治疗提供新策略。方法收集2018年1月至2019年1月SiewertⅠ型贲门癌患者72例,常规化疗(新辅助组)或联合阿帕替尼(apa+新辅助组)2周期后行手术治疗,分析患者病理退缩率、R0切除率、术后并发症等差异。结果 2组化疗不良反应发生率差异无统计学意义(P>0.05)。全部患者均接受Ivor-Lewis手术,其中微创腔镜手术73.61%(53/72,apa+新辅助组26例,新辅助组27例)。2组R0切除率均为100%,术后并发症发生率差异无统计学意义(P>0.05)。病理反应率优于新辅助组(P=0.034),病理1～2级缓解率apa+新辅助组(n=36,100%)优于新辅助组(n=30,83.33%)(P=0.033);apa+新辅助组术后T分期的T1比例优于新辅助组(P=0.028)。结论小剂量阿帕替尼联合替吉奥/顺铂化疗是SiewertⅠ型贲门癌新辅助治疗的安全、有效手段。更多还原

【Abstract】 Objective To investigate the Therapeutic effects of low dose apatinib combined with S1/cisplatin neoadjuvant chemotherapy in treatment of Siewert Ⅰgastric cardia cancer(AEG) in elderly patients.Methods A total of 72 elderly patients with Siewert Ⅰ AEG were enrolled in the study, who were divided into control group and observation group.The patients in control group were treated by routine chemotherapy, however, the patients in observation group, on the basis of control group, were treated by apatinib.After two treatment courses, the patients in both groups were treated by surgery.The pathological reaction rate, R0 resection rate, postoperative complicatins were observed and compared between the two groups.Results The patients in both groups underwent Ivor-Lewis surgery, in which, micro-invasive telescopic surgery accounted for 73.61%(53/72),including 27 cases in control group and 26 cases in observation group.The R0 resection rate was 100% in both groups.There was no significant difference in the incidence of postoperative complicatins between the two groups(P>0.05). Moreover the pathological reaction rate and remission rate of pathological 1～2 grade in observation group were superior to those in control group(P<0.05).Conclusion The low-dose apatinib combined with apatinib/cisplatin chemotherapy is a safe and effective neoadjuvant therapy measure for Siewert Ⅰ AEG.更多还原